Sowell Financial Services LLC lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 6.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,842 shares of the medical research company’s stock after purchasing an additional 1,042 shares during the quarter. Sowell Financial Services LLC’s holdings in Amgen were worth $3,872,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently added to or reduced their stakes in the stock. Kingsview Wealth Management LLC grew its holdings in shares of Amgen by 5.9% during the 3rd quarter. Kingsview Wealth Management LLC now owns 42,091 shares of the medical research company’s stock worth $10,697,000 after purchasing an additional 2,339 shares in the last quarter. Perkins Coie Trust Co boosted its position in shares of Amgen by 7.7% during the fourth quarter. Perkins Coie Trust Co now owns 1,665 shares of the medical research company’s stock worth $383,000 after buying an additional 119 shares during the period. Burns J W & Co. Inc. NY boosted its position in shares of Amgen by 2.2% during the fourth quarter. Burns J W & Co. Inc. NY now owns 24,193 shares of the medical research company’s stock worth $5,563,000 after buying an additional 510 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in shares of Amgen during the third quarter worth about $3,994,000. Finally, Banco Bilbao Vizcaya Argentaria S.A. boosted its position in shares of Amgen by 11.8% during the third quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 25,748 shares of the medical research company’s stock worth $6,544,000 after buying an additional 2,720 shares during the period. Institutional investors and hedge funds own 75.23% of the company’s stock.
AMGN has been the subject of several recent research reports. Cantor Fitzgerald reduced their price objective on Amgen from $279.00 to $278.00 and set an “overweight” rating for the company in a research report on Thursday, October 29th. Raymond James raised Amgen from a “market perform” rating to an “outperform” rating and set a $255.00 price objective for the company in a research report on Monday, October 26th. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Amgen in a research report on Sunday, December 27th. BidaskClub raised Amgen from a “strong sell” rating to a “sell” rating in a research report on Friday, January 1st. Finally, Credit Suisse Group reduced their price target on Amgen from $286.00 to $284.00 and set an “outperform” rating for the company in a research report on Tuesday, October 27th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eighteen have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $254.92.
Amgen (NASDAQ:AMGN) last announced its earnings results on Monday, November 2nd. The medical research company reported $4.37 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.75 by $0.62. The company had revenue of $6.42 billion for the quarter, compared to analyst estimates of $6.38 billion. Amgen had a return on equity of 95.55% and a net margin of 29.42%. Equities research analysts expect that Amgen Inc. will post 16.15 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, March 8th. Stockholders of record on Monday, February 15th will be paid a dividend of $1.76 per share. The ex-dividend date is Thursday, February 11th. This represents a $7.04 dividend on an annualized basis and a dividend yield of 2.96%. This is a positive change from Amgen’s previous quarterly dividend of $1.60. Amgen’s dividend payout ratio (DPR) is 43.18%.
In other news, Director R Sanders Williams sold 250 shares of the stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $242.40, for a total transaction of $60,600.00. Following the transaction, the director now owns 4,909 shares in the company, valued at $1,189,941.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.36% of the stock is currently owned by company insiders.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.
Featured Story: Day Trading – Risk Worth the Reward?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.